Therapy with Metronomic Cyclophosphamide for Previously-Treated Metastatic Castrate-Resistant Prostate Cancer

Oral, low-dose metronomic cyclophosphamide (mCyc) has been shown to have activity in the treatment of metastatic prostate cancer. In addition to multiple historical studies demonstrating the efficacy of this therapy, it is also well tolerated, easily accessible, and extremely cost effective due to being off patent.

Unfortunately, the use of mCyc has fallen out of favor with the development of modern therapies for metastatic prostate cancer. This article aims to re-introduce mCyc to modern oncology providers as a viable treatment option for patients with metastatic castrate-resitant prostate cancer and possibly inspire future research studies with this agent.

Written by: Nataliya Mar, MD, Clinical Associate Professor, Division of Hematology/Oncology, University of California Irvine, Irvine, CA

Read the Abstract

Login